Bellerophon Therapeutics Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 4/6

Bellerophon Therapeutics hat ein Gesamteigenkapital von $3.7M und eine Gesamtverschuldung von $0.0, was einen Verschuldungsgrad von 0% ergibt. Die Gesamtaktiva und Gesamtpassiva betragen $5.0M bzw. $1.3M.

Wichtige Informationen

Verhältnis von Schulden zu Eigenkapital

US$0

Verschuldung

Zinsdeckungsgrad	n/a
Bargeld	US$4.38m
Eigenkapital	US$3.72m
Gesamtverbindlichkeiten	US$1.26m
Gesamtvermögen	US$4.98m

Jüngste Berichte zur Finanzlage

Bellerophon Therapeutics (NASDAQ:BLPH) Will Have To Spend Its Cash Wisely

Jan 06

Is Bellerophon Therapeutics (NASDAQ:BLPH) In A Good Position To Invest In Growth?

Jan 18

Recent updates

Is Bellerophon Therapeutics (NASDAQ:BLPH) In A Good Position To Invest In Growth?

Jan 18

Bellerophon Therapeutics EPS misses by $0.01

Nov 05

Analyse der Finanzlage

Kurzfristige Verbindlichkeiten: BLPHDie kurzfristigen Aktiva des Unternehmens ($5.0M) übersteigen seine kurzfristigen Passiva ($1.3M).

Langfristige Verbindlichkeiten: BLPH hat keine langfristigen Verbindlichkeiten.

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Verschuldungsgrad: BLPH ist schuldenfrei.

Schulden abbauen: BLPH hat in den letzten 5 Jahren keine Schulden gemacht.

Bilanz

Liquiditätsreserve-Analyse

Bei Unternehmen, die in der Vergangenheit im Durchschnitt Verluste gemacht haben, wird geprüft, ob sie über einen Liquiditätsvorlauf von mindestens einem Jahr verfügen.

Stabile Start- und Landebahn für Bargeld: BLPH hat auf der Grundlage seines derzeitigen freier Cashflows weniger als ein Jahr Liquiditätsspielraum.

Vorhersage Cash Runway: BLPH hat weniger als ein Jahr Liquiditätsreserven, wenn der freie Cashflow weiterhin mit den historischen Raten von 2.1% pro Jahr abnimmt

Bellerophon Therapeutics Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 4/6

Wichtige Informationen

Jüngste Berichte zur Finanzlage

Bellerophon Therapeutics, Inc. Files Form 15

Bellerophon Therapeutics to Be Delisted from the Nasdaq Capital Market At Opening of Business on July 28, 2023 Unless It Timely Requests A Hearing Before Nasdaq Hearings Panel to Address Deficiencies and Present Plan to Regain Compliance

Bellerophon Therapeutics (NASDAQ:BLPH) Will Have To Spend Its Cash Wisely

Is Bellerophon Therapeutics (NASDAQ:BLPH) In A Good Position To Invest In Growth?

Recent updates

Bellerophon Therapeutics, Inc. Files Form 15

Bellerophon Therapeutics, Inc. Announces Executive Changes

Bellerophon Therapeutics, Inc. Announces Resignation of Theodore Wang as a Member of the Company's Board

New major risk - Share price stability

New major risk - Financial position

New major risk - Revenue and earnings growth

Bellerophon Therapeutics to Be Delisted from the Nasdaq Capital Market At Opening of Business on July 28, 2023 Unless It Timely Requests A Hearing Before Nasdaq Hearings Panel to Address Deficiencies and Present Plan to Regain Compliance

Bellerophon Therapeutics, Inc. Announces Resignation of Crispin Teufel as Board of Director

New major risk - Financial position

New major risk - Market cap size

Consensus EPS estimates fall by 21%

Bellerophon Therapeutics, Inc. Announces Top-Line Data from Phase 3 REBUILD Clinical Trial of INOpulse® for Treatment of Fibrotic Interstitial Lung Disease

Price target decreased by 8.0% to US$25.75

Insider recently sold US$82k worth of stock

Consensus revenue estimates increase by 157%

Bellerophon Therapeutics, Inc. Announces Last Patient Has Completed Blinded Treatment in Phase 3 REBUILD Study for INOpulse® in Fibrotic Interstitial Lung Disease

Consensus revenue estimates fall by 20%

Forecast to breakeven in 2025

Bellerophon Therapeutics, Inc. Receives IND Clearance from China NMPA to Conduct Phase 3 Clinical Trial in China for INOpulse(R) in Fibrotic Interstitial Lung Disease

Bellerophon Therapeutics, Inc. Announces Completion of Enrollment in Phase 3 REBUILD Study for INOpulse® in Fibrotic Interstitial Lung Disease

Bellerophon Therapeutics (NASDAQ:BLPH) Will Have To Spend Its Cash Wisely

Price target decreased to US$24.50

Insufficient new directors

Bellerophon Provides Clinical Program Update

Bellerophon Announces FDA Acceptance of Change to Ongoing Phase 3 Rebuild Study of Inopulse for Treatment of Fibrotic Interstitial Lung Disease

Bellerophon stock gains ~24% after getting FDA nod to reduce phase 3 study size

Bellerophon Therapeutics GAAP EPS of -$0.43 beats by $0.17

Bellerophon Therapeutics, Inc. Announces New Board Appointment

Price target decreased to US$24.50

Insufficient new directors

Bellerophon Therapeutics, Inc., Annual General Meeting, Jun 01, 2022

Insufficient new directors

Is Bellerophon Therapeutics (NASDAQ:BLPH) In A Good Position To Invest In Growth?

Bellerophon Therapeutics, Inc. Reports Positive Top-Line Data from Phase 2 Acute Dose Escalation Study of Inopulse® for Treatment of Pulmonary Hypertension Associated with Sarcoidosis

CFO & Secretary Assaf Korner has left the company

Price target decreased to US$25.00

Bellerophon Therapeutics, Inc. Provides Clinical Program Update

Bellerophon Therapeutics, Inc.(NasdaqCM:BLPH) dropped from Russell 3000E Index

Bellerophon Therapeutics, Inc. Provides Clinical Program Update

Bellerophon Therapeutics Announces First Patient Enrolled in Phase 3 REBUILD Study Evaluating INOpulse® for the Treatment of Fibrotic Interstitial Lung Disease

Bellerophon Therapeutics, Inc. Announces Results of Interim Analysis of Phase 3 COViNOX Study of INOpulse for the Treatment of COVID-19

Bellerophon Therapeutics EPS misses by $0.01

Analyse der Finanzlage

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Bilanz

Liquiditätsreserve-Analyse

Entdecken Sie finanziell stabile Unternehmen